Evidence map›Paper›PMID 41263155›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

Red and Orange-Light-Accelerated Rhodium-Catalyzed Oxidative Olefination of Arenes.

Antônio Junio Araujo Dias, Ken Tanaka, Masanobu Uchiyama, Yuki Nagashima

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Antônio Junio Araujo DiasDepartment of Chemical Science and Engineering, Institute of Science Tokyo, Tokyo, Japan.
Ken TanakaDepartment of Chemical Science and Engineering, Institute of Science Tokyo, Tokyo, Japan.
Masanobu UchiyamaGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Yuki NagashimaDepartment of Chemical Science and Engineering, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8470-5638

Funding

Asahi Glass FoundationFusion Oriented REsearch for disruptive Science and Technology JPMJFR221YJapan Society for the Promotion of Science 23H01956Japan Society for the Promotion of Science 23KJ0952Japan Society for the Promotion of Science 24H01067Japan Society for the Promotion of Science 24H01839Japan Society for the Promotion of Science 24K21762Uehara Memorial Foundation
6 · The paper itself

Abstract

Transition metal (TM)-catalyzed photoreactions have emerged as powerful tools for synthesizing products that are challenging to obtain under conventional thermal conditions. However, most protocols rely on short-wavelength visible light, such as purple or blue light (<500 nm). Although long-wavelength light (>500 nm) allows for milder conditions, higher chemical selectivity, and deep light penetration, its application in single TM-catalyzed photocatalytic systems is rare. Herein, we present the long-wavelength visible-light-accelerated Rh(III)-catalyzed olefination of arenes bearing an anilide moiety as a directing group. This methodology circumvents the use of external photosensitizers and short-wavelength blue light, owing to the use of a cationic Rh(III) complex. Experimental and computational analyses suggest that the Rh(III) complex initially acts as a C─H activation catalyst, and oxidation of the generated Rh(III) hydride intermediate by oxygen is accelerated by absorption of long-wavelength visible light (> 500 nm).

Indexed as

C─H olefinationDFT calculationslong‐wavelength lightphoto‐accelerated reactionrhodium(III) catalyst

Identifiers

PMID41263155
PMCPMC12734672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.